PROQR THERAPEUTICS NV (PRQR) Stock Fundamental Analysis

NASDAQ:PRQR • NL0010872495

1.49 USD
+0.04 (+2.76%)
Last: Feb 18, 2026, 08:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Overall PRQR gets a fundamental rating of 2 out of 10. We evaluated PRQR against 521 industry peers in the Biotechnology industry. PRQR may be in some trouble as it scores bad on both profitability and health. PRQR is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year PRQR has reported negative net income.
  • In the past year PRQR has reported a negative cash flow from operations.
  • PRQR had negative earnings in each of the past 5 years.
  • In the past 5 years PRQR reported 4 times negative operating cash flow.
PRQR Yearly Net Income VS EBIT VS OCF VS FCFPRQR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

  • With a decent Return On Assets value of -34.23%, PRQR is doing good in the industry, outperforming 62.57% of the companies in the same industry.
  • PRQR has a Return On Equity of -74.59%. This is comparable to the rest of the industry: PRQR outperforms 54.51% of its industry peers.
Industry RankSector Rank
ROA -34.23%
ROE -74.59%
ROIC N/A
ROA(3y)-24.98%
ROA(5y)-30.3%
ROE(3y)-66.23%
ROE(5y)-66.88%
ROIC(3y)N/A
ROIC(5y)N/A
PRQR Yearly ROA, ROE, ROICPRQR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

  • PRQR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRQR Yearly Profit, Operating, Gross MarginsPRQR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K -2.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • PRQR does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, PRQR has more shares outstanding
  • The number of shares outstanding for PRQR has been increased compared to 5 years ago.
  • Compared to 1 year ago, PRQR has an improved debt to assets ratio.
PRQR Yearly Shares OutstandingPRQR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
PRQR Yearly Total Debt VS Total AssetsPRQR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • Based on the Altman-Z score of -4.28, we must say that PRQR is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -4.28, PRQR is in line with its industry, outperforming 41.65% of the companies in the same industry.
  • PRQR has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of PRQR (0.18) is worse than 64.49% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Altman-Z -4.28
ROIC/WACCN/A
WACC7%
PRQR Yearly LT Debt VS Equity VS FCFPRQR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 3.36 indicates that PRQR has no problem at all paying its short term obligations.
  • The Current ratio of PRQR (3.36) is comparable to the rest of the industry.
  • PRQR has a Quick Ratio of 3.36. This indicates that PRQR is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 3.36, PRQR perfoms like the industry average, outperforming 42.99% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.36
Quick Ratio 3.36
PRQR Yearly Current Assets VS Current LiabilitesPRQR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • PRQR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -42.62%.
  • The Revenue for PRQR has decreased by -24.60% in the past year. This is quite bad
  • PRQR shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 58.89% yearly.
EPS 1Y (TTM)-42.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-24.6%
Revenue growth 3Y101.19%
Revenue growth 5Y58.89%
Sales Q2Q%-25.01%

3.2 Future

  • Based on estimates for the next years, PRQR will show a very negative growth in Earnings Per Share. The EPS will decrease by -23.97% on average per year.
  • The Revenue is expected to grow by 35.74% on average over the next years. This is a very strong growth
EPS Next Y-39.17%
EPS Next 2Y-33.29%
EPS Next 3Y-23.97%
EPS Next 5YN/A
Revenue Next Year-24.87%
Revenue Next 2Y-5.67%
Revenue Next 3Y-13.92%
Revenue Next 5Y35.74%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
PRQR Yearly Revenue VS EstimatesPRQR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M 500M
PRQR Yearly EPS VS EstimatesPRQR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • PRQR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year PRQR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRQR Price Earnings VS Forward Price EarningsPRQR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRQR Per share dataPRQR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6 -0.6

4.3 Compensation for Growth

  • A cheap valuation may be justified as PRQR's earnings are expected to decrease with -23.97% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-33.29%
EPS Next 3Y-23.97%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • PRQR does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PROQR THERAPEUTICS NV

NASDAQ:PRQR (2/18/2026, 8:00:00 PM)

1.49

+0.04 (+2.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)02-19
Inst Owners36.54%
Inst Owner Change-7.45%
Ins Owners2%
Ins Owner ChangeN/A
Market Cap156.97M
Revenue(TTM)16.07M
Net Income(TTM)-42.57M
Analysts85.33
Price Target9.82 (559.06%)
Short Float %2.07%
Short Ratio3.2
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-19.4%
Min EPS beat(2)-43.58%
Max EPS beat(2)4.77%
EPS beat(4)2
Avg EPS beat(4)-11.12%
Min EPS beat(4)-43.58%
Max EPS beat(4)4.77%
EPS beat(8)5
Avg EPS beat(8)-84.26%
EPS beat(12)9
Avg EPS beat(12)-51.87%
EPS beat(16)11
Avg EPS beat(16)-43.54%
Revenue beat(2)0
Avg Revenue beat(2)-25.59%
Min Revenue beat(2)-35.24%
Max Revenue beat(2)-15.94%
Revenue beat(4)0
Avg Revenue beat(4)-20.41%
Min Revenue beat(4)-35.24%
Max Revenue beat(4)-2.1%
Revenue beat(8)1
Avg Revenue beat(8)-26.65%
Revenue beat(12)2
Avg Revenue beat(12)-24.13%
Revenue beat(16)6
Avg Revenue beat(16)-7.08%
PT rev (1m)0.56%
PT rev (3m)6.94%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.79%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.74%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.65%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-8.37%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.24
P/FCF N/A
P/OCF N/A
P/B 2.32
P/tB 2.32
EV/EBITDA N/A
EPS(TTM)-0.49
EYN/A
EPS(NY)-0.66
Fwd EYN/A
FCF(TTM)-0.56
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS0.18
BVpS0.64
TBVpS0.64
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -34.23%
ROE -74.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-24.98%
ROA(5y)-30.3%
ROE(3y)-66.23%
ROE(5y)-66.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 23.27%
Cap/Sales 3.9%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.36
Quick Ratio 3.36
Altman-Z -4.28
F-Score2
WACC7%
ROIC/WACCN/A
Cap/Depr(3y)44.7%
Cap/Depr(5y)38.73%
Cap/Sales(3y)12.15%
Cap/Sales(5y)13.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-42.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-39.17%
EPS Next 2Y-33.29%
EPS Next 3Y-23.97%
EPS Next 5YN/A
Revenue 1Y (TTM)-24.6%
Revenue growth 3Y101.19%
Revenue growth 5Y58.89%
Sales Q2Q%-25.01%
Revenue Next Year-24.87%
Revenue Next 2Y-5.67%
Revenue Next 3Y-13.92%
Revenue Next 5Y35.74%
EBIT growth 1Y-66.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-38.73%
EBIT Next 3Y-16.57%
EBIT Next 5YN/A
FCF growth 1Y-696.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-639.62%
OCF growth 3YN/A
OCF growth 5YN/A

PROQR THERAPEUTICS NV / PRQR FAQ

What is the ChartMill fundamental rating of PROQR THERAPEUTICS NV (PRQR) stock?

ChartMill assigns a fundamental rating of 2 / 10 to PRQR.


Can you provide the valuation status for PROQR THERAPEUTICS NV?

ChartMill assigns a valuation rating of 0 / 10 to PROQR THERAPEUTICS NV (PRQR). This can be considered as Overvalued.


What is the profitability of PRQR stock?

PROQR THERAPEUTICS NV (PRQR) has a profitability rating of 1 / 10.


What is the financial health of PROQR THERAPEUTICS NV (PRQR) stock?

The financial health rating of PROQR THERAPEUTICS NV (PRQR) is 3 / 10.


What is the expected EPS growth for PROQR THERAPEUTICS NV (PRQR) stock?

The Earnings per Share (EPS) of PROQR THERAPEUTICS NV (PRQR) is expected to decline by -39.17% in the next year.